| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2228
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4705 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57509 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2017-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c11ac4a0d608882c73170d8144cce84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4253075af0aeede8d90213bf3c420ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_571a29cf26486f8132d135a11554db2b |
| publicationDate |
2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2901477-T3 |
| titleOfInvention |
Novel fatty acid-modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease |
| abstract |
A compound of Formula: wherein X1 denotes that residue I is modified by acetylation or methylation at the N-terminus; where X2 is L or T; where X3 is L or I; where X4 is Q or E; and wherein a modified K residue ("K*") at position 29 is modified by conjugation with the K side chain epsilon-amino group with a group of the formula -X5-X6, where -X5- X6 is ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γE)2-CO-(CH2)x-CO2H where x is 16 or 18; or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2016-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |